Evidence map›Paper›PMID 37319168›Full record

ArticlePloS one2023

Model based on COVID-19 evidence to predict and improve pandemic control.

Rafael I González, Pablo S Moya, Eduardo M Bringa, Gonzalo Bacigalupe, Muriel Ramírez-Santana, Miguel Kiwi

Abstract read
In one paragraph

Article in PloS one, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rafael I GonzálezCentro de Nanotecnología Aplicada, Universidad Mayor, Santiago, Chile.ORCID 0000-0003-2599-8404
Pablo S MoyaDepartamento de Física, Facultad de Ciencias, Universidad de Chile, Santiago, Chile.ORCID 0000-0002-9161-0888
Eduardo M BringaCentro de Nanotecnología Aplicada, Universidad Mayor, Santiago, Chile.
Gonzalo BacigalupeSchool of Education and Human Development, University of Massachusetts Boston, Boston, MA, United States of America.ORCID 0000-0002-9302-3361
Muriel Ramírez-SantanaDepartamento de Salud Pública, Facultad de Medicina, Universidad Católica del Norte, Coquimbo, Chile.
Miguel KiwiCenter for the Development of Nanoscience and Nanotechnology, CEDENNA, Santiago, Chile.ORCID 0000-0001-8580-1912

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Based on the extensive data accumulated during the COVID-19 pandemic, we put forward simple to implement indicators, that should alert authorities and provide early warnings of an impending sanitary crisis. In fact, Testing, Tracing, and Isolation (TTI) in conjunction with disciplined social distancing and vaccination were expected to achieve negligible COVID-19 contagion levels; however, they proved to be insufficient, and their implementation has led to controversial social, economic and ethical challenges. This paper focuses on the development of simple indicators, based on the experience gained by COVID-19 data, which provide a sort of yellow light as to when an epidemic might expand, despite some short term decrements. We show that if case growth is not stopped during the 7 to 14 days after onset, the growth risk increases considerably, and warrants immediate attention. Our model examines not only the COVID contagion propagation speed, but also how it accelerates as a function of time. We identify trends that emerge under the various policies that were applied, as well as their differences among countries. The data for all countries was obtained from ourworldindata.org. Our main conclusion is that if the reduction spread is lost during one, or at most two weeks, urgent measures should be implemented to avoid scenarios in which the epidemic gains strong impetus.

Indexed as

COVID-19HumansPandemicsSARS-CoV-2

Identifiers

PMID37319168
PMCPMC10270358

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.